SCHEMBL622716

SCHEMBL622716

CC(C)COc1cc(N2CCN(C(=O)CCOc3ccccc3)CC2)ncn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.53
SMN1; SMN2 Q16637 6/20 0.53
RAB9A P51151 6/20 0.53
KDM4E B2RXH2 4/20 0.53
ALDH1A1 P00352 4/20 0.53
KMT2A Q03164 3/20 0.53
TSHR P16473 2/20 0.53
MAPK1 P28482 2/20 0.53
HSD17B10 Q99714 2/20 0.53
MAPT P10636 6/20 0.52
GAA P10253 3/20 0.52
POLB P06746 1/20 0.45
HPGD P15428 3/20 0.44
PKM P14618 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
RECQL P46063 1/20 0.42
TGM2 P21980 1/20 0.41
MEN1 O00255 1/20 0.41
CHRM4 P08173 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL624233 0.91 MAPT (0.45) NPC1SMN1; SMN2RAB9AKDM4EALDH1A1
SCHEMBL624188 0.90 MAPT (0.46) NPC1SMN1; SMN2RAB9AKDM4EALDH1A1
SCHEMBL624464 0.90 KMT2A (0.54) SMN1; SMN2KDM4EALDH1A1KMT2AMAPK1
SCHEMBL622875 0.83 HSD17B10 (0.53) KDM4EALDH1A1KMT2ATSHRHSD17B10
SCHEMBL622874 0.83 HSD17B10 (0.53) KDM4EALDH1A1KMT2ATSHRHSD17B10
SCHEMBL624361 0.82 ALDH1A1 (0.57) NPC1SMN1; SMN2RAB9AKDM4EALDH1A1
SCHEMBL623463 0.81 POLB (0.47) NPC1SMN1; SMN2RAB9AKDM4EALDH1A1
SCHEMBL623224 0.81 GRM5 (0.60)
SCHEMBL624044 0.81 CKS1B (0.41) SMN1; SMN2ALDH1A1POLB
SCHEMBL622833 0.81 LOXL2 (0.43) NPC1SMN1; SMN2ALDH1A1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G NPC1 785/4885SMN1; SMN2 598/4885RAB9A 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.